Immune-mediated disease specialist Provention Bio (Nasdaq: PRVB) has presented data from the At-Risk study, testing its type 1 diabetes (T1D) candidate PRV-031 (teplizumab).
Results from the study, which is evaluating the anti-CD3 monoclonal antibody for the prevention or delay of clinical T1D, were presented at the annual American Diabetes Association (ADA) meeting.
Results from the study showed that a single 14-day course of teplizumab significantly delayed the onset and diagnosis of clinical T1D, as compared to placebo, by a median of two years in children and adults considered to be at high risk.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze